ABNX Stock Overview
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
ABIONYX Pharma SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.02 |
| 52 Week High | €2.16 |
| 52 Week Low | €0.91 |
| Beta | -0.12 |
| 1 Month Change | 10.89% |
| 3 Month Change | -18.56% |
| 1 Year Change | -43.94% |
| 3 Year Change | -8.45% |
| 5 Year Change | 168.60% |
| Change since IPO | -91.74% |
Recent News & Updates
Shareholder Returns
| ABNX | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -5.2% | -0.06% | -0.2% |
| 1Y | -43.9% | -4.3% | 2.4% |
Return vs Industry: ABNX underperformed the French Biotechs industry which returned -8.2% over the past year.
Return vs Market: ABNX underperformed the French Market which returned 4% over the past year.
Price Volatility
| ABNX volatility | |
|---|---|
| ABNX Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ABNX has not had significant price volatility in the past 3 months.
Volatility Over Time: ABNX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 63 | Cyrille Tupin | abionyx.com |
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019.
ABIONYX Pharma SA Fundamentals Summary
| ABNX fundamental statistics | |
|---|---|
| Market cap | €32.78m |
| Earnings (TTM) | -€3.50m |
| Revenue (TTM) | €4.60m |
7.1x
P/S Ratio-9.4x
P/E RatioIs ABNX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABNX income statement (TTM) | |
|---|---|
| Revenue | €4.60m |
| Cost of Revenue | €4.00m |
| Gross Profit | €600.00k |
| Other Expenses | €4.10m |
| Earnings | -€3.50m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Sep 26, 2024
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 13.04% |
| Net Profit Margin | -76.09% |
| Debt/Equity Ratio | 89.8% |
How did ABNX perform over the long term?
See historical performance and comparison